What is OWKIN?
Headquartered in New York, Owkin operates at the vanguard of the digital health revolution. The company specializes in developing interpretable artificial intelligence models that allow researchers to harness fragmented data from healthcare and research environments. By facilitating secure, federated learning, Owkin enables the training of sophisticated algorithms without compromising patient privacy or data sovereignty. This unique value proposition positions the firm as an essential partner for pharmaceutical companies and academic institutions seeking to accelerate drug discovery and optimize clinical development pipelines through high-fidelity predictive analytics.
How much funding has OWKIN raised?
OWKIN has raised a total of $225.1M across 4 funding rounds:
Angel/Seed
$2.1M
Other Financing Round
$25M
Series A
$18M
Private Equity
$180M
Angel/Seed (2016): $2.1M, investors not publicly disclosed
Other Financing Round (2020): $25M led by Bpifrance Large Venture
Series A (2020): $18M supported by Bpifrance and Mubadala GE Capital PJSC
Private Equity (2021): $180M featuring Sanofi
Key Investors in OWKIN
Sanofi
A global biopharmaceutical leader focused on scientific innovation across immunology, oncology, and rare diseases, providing both capital and deep industry expertise to accelerate medical breakthroughs.
Bpifrance
A French public investment bank that supports the growth of innovative companies through equity, credit, and strategic acceleration programs.
Mubadala GE Capital PJSC
A diversified investment firm that provides strategic capital to high-growth enterprises, focusing on long-term value creation and global market expansion.
What's next for OWKIN?
With the recent influx of capital, Owkin is well-positioned to expand its footprint in the global biopharmaceutical ecosystem. The strategic focus will likely shift toward deepening its integration with large-scale clinical trial networks and enhancing its suite of diagnostic tools. As the industry moves toward precision medicine, Owkin's ability to provide transparent, explainable AI will be a critical differentiator. Future growth will likely involve scaling its operational infrastructure to support multi-center research collaborations, further cementing its role as a foundational layer in the next generation of data-driven medical innovation.
See full OWKIN company page
